BridgeBio Posts $180.6M Attruby Revenue, Authorizes $500M Buyback
BridgeBio posts $180.6M Attruby revenue in Q1 2026, authorizing $500M buyback as the rare disease drug drives commercial expansion.
Crinetics’ Palsonify Reaches 70% Reimbursement Rate in Q1 2026 Launch
Crinetics' Palsonify achieves 70% reimbursement rate in Q1 2026 launch, nearly doubling sequential revenue with 232 new patient enrollments.
MoonLake’s Sonelokimab Clears FDA Pre-BLA Meeting for Hidradenitis Suppurativa
MoonLake's sonelokimab for hidradenitis suppurativa achieved a 29-percentage-point placebo-adjusted response rate, positioning it above current competitors in F
Amneal Specialty Segment Grows 23% in Q1 2026 as Branded Portfolio Expands
Amneal's specialty segment grows 23% in Q1 2026, driven by branded neurology and endocrinology portfolio expansion and margin improvement.
Oragenics to License CardioDialysis Technology for TBI Treatment
Oragenics licenses CardioDialysis technology for TBI treatment using preferred stock, targeting post-injury neuroinflammation through dual mechanisms.
Crinetics Reports Paltusotine Q1 Revenue of $10.3M, Doubles Sequentially
Crinetics' paltusotine Q1 revenue reached $10.3M, doubling sequentially from Q4 2025 with 70% patient reimbursement rate achieved.
Zymeworks Awaits August 2026 Zanidatamab Approval Decision in Gastric Cancer
Zymeworks awaits zanidatamab approval decision on August 25, 2026, for first-line HER2-positive gastroesophageal adenocarcinoma, triggering a $250 million miles
Genmab Q1 2026 Royalty Revenue Rises 26% as DARZALEX Drives Growth
Genmab's Q1 2026 royalty revenue rises 26% to $742M, driven by DARZALEX sales growth through Johnson & Johnson partnerships.
BridgeBio Reports $180.6M Attruby Revenue, Authorizes $500M Buyback
BridgeBio reports $180.6M in Attruby revenue for Q1 2026, while authorizing a $500M share buyback and advancing three pipeline...
Oragenics to License CardioDialysis Technology From Sigyn for TBI Treatment
Oragenics licenses CardioDialysis Technology from Sigyn to combine with ONP-002 for treating traumatic brain injury inflammation.